Cancer patients gain equal pricing for oral vs. IV drugs under new parity rule

What it does

This bill requires group health plans to charge patients the same out-of-pocket costs for oral cancer drugs (pills taken at home) as they do for intravenous cancer drugs administered in a clinic or hospital. It prevents insurers from raising costs, reclassifying benefits, or imposing stricter limits on oral drugs to comply. The bill takes effect January 1, 2026, and directs the Government Accountability Office to study its impact within two years.

Why we flagged it

The bill's core mechanism is a regulatory mandate requiring equal cost-sharing treatment for two drug delivery methods. It is a consumer-protection measure that constrains insurer pricing discretion, not a subsidy or carve-out.

What the text implies

• Oral anticancer drugs may become more attractive to insurers as a cost-containment strategy if they are genuinely cheaper to produce/dispense than IV drugs; parity pricing could shift treatment patterns toward oral formulations.
• The bill does not mandate coverage of oral anticancer drugs—only equal cost-sharing if covered. Insurers retain the right to exclude drugs or impose prior authorization, limiting the practical benefit for some patients.
• The GAO study (due 2 years post-enactment) may reveal that parity pricing increases overall plan costs, potentially triggering insurer responses such as higher premiums or narrower drug formularies.
• State laws providing greater protections are preserved, creating a patchwork of coverage rules across jurisdictions and potentially complicating multi-state plan administration.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Cancer patients gain access to oral medications at the same cost as IV alternatives, removing a financial barrier to treatment. The bill explicitly prohibits insurers from circumventing the requirement by raising costs or reclassifying benefits, protecting patients from cost-shifting.

Who stands to gain

• cancer patients (reduced out-of-pocket costs for oral medications)
• pharmaceutical manufacturers of oral anticancer drugs (potential increased demand if cost parity rem

Named in the bill

Employee Retirement Income Security Act of 1974 (ERISA), group health plans, health insurance issuers, Food and Drug Administration (FDA), Government Accountability Office (GAO), Comptroller General of the United States

Where it stands

31 cosponsors: 26 Democrats, 5 Republicans.

• Jun 24, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 24, 2025 — Referred to House Committee on Education and Workforce · Congress.gov: “Referred to the House Committee on Education and Workforce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $650,000 in lobbying spend. A filing names 25 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Glenn Grothman, the sponsor, reported $325,000 in PAC receipts in the 2026 cycle.

• Association for Clinical Oncology — $600,000 on 2 filings
• Hematology Oncology Pharmacy Association — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.